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ABSTRACT: Nine new minor diterpenoids, jatrogossones A−I (1−9), and six known 
analogues (10−15) were separated from an extract of the branches and leaves of 
Jatropha gosspiifolia. Compounds 4−6 and 10, possessing a 5/11 fused-ring skeleton, 
and 8, 9, and 13 with a 5/9/5 fused-ring skeleton represent rare diterpenoid skeletons 
that have been found only in compounds isolated from plants of the Jatropha genus. 
The absolute configurations of 1−10 were defined by using a combination of electronic 
circular dichroism data analysis and single-crystal X-ray diffraction data. The 
cytotoxicity of the diterpenoids were evaluated using RKO and LOVO colon cancer 
cells in which regenerating islet-derived protein 3-alpha (Reg3A) is highly expressed. 
Compound 12 exhibited cytotoxicity against RKO colon cancer cells with an IC50 value 
of 2.6 M. Morphological features of apoptosis and antimigration activities were 
evaluated in 12-treated RKO cells. Compound 12 effectively induced apoptosis of RKO, 
which was associated with G2/M-phase cell cycle arrest. Flow cytometric analysis 
showed that the treatment by 12 significantly induced RKO cell apoptosis in a dose-
dependent manner. 
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Colorectal cancer (CRC) is the third and the second most commonly diagnosed tumor 
in men and women, respectively, worldwide.1 In the U.S. alone, approximately 140 000 
people are diagnosed annually with CRC, and among these, 50 000 have died of this 
malignant disease.2 Considering the high morbidity and low effectiveness of colon 
cancer treatment, there is a need for new strategies that can prevent and cure this disease. 
Colorectal carcinogenesis is a multistep process that offers opportunities for preventive 
interventions.3 The critical role of Reg3A has been well-established in CRC, and 
selective Reg3A inhibitors have recently been regarded as an elegant example for CRC 
chemoprevention.4 Therefore, identifying new preventive agents against Reg3A is 
thought to be an essential step towards the discovery of molecular targets for CRC 
chemoprevention. 
Jatropha gossypiifolia L. (Euphorbiaceae) is widely distributed in countries of 
tropical, subtropical, and dry tropical weather and tropical semiarid regions of 
Africa and the Americas.5 It is used in folk medicine for various purposes, such as 
analgesic, anti-inflammatory, antihemorrhagic, hemostatic, and an antidote for 
snakebites.5,6 Previous phytochemical investigations of J. gossypiifolia led to the 
isolation of numerous diterpenoids,7-10 lignans,11,12 cyclic peptides,13 and 
triterpenoids,14 some of which showed anticancer9 and antibacterial activities.7 As 
part of an ongoing effort to discover natural products with anticancer activities,15,16 
the petroleum ether fraction of J. gossypiifolia showed inhibitory activities against 
a panel of human cancer cells. Chemical investigation of petroleum ether extracts 
led to the isolation of nine new diterpenoids (1−9) and six known analogues (10−15). 
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Compounds 1−15 displayed cytotoxicity against RKO and LOVO colon cancer cells, 
with IC50 values in the range of 2.6 to 18.6 M. Herein, the isolation, structural 
elucidation, and assessment of compound 12’s ability to induce apoptosis and arrest 
the cell cycle in RKO human colon cancer cells are reported. 
RESULTS AND DISCUSSION 
Compound 1 had a molecular formula of C22H30O4, as established by the HRESIMS 
ion at m/z 376.2479 [M + NH4]+ (calcd for C22H34O4N, 376.2482). The IR absorption 
bands at 1735, 1717, and 1686 cm1 were indicative of the presence of ester carbonyl 
and conjugated carbonyl functionalities. Its 1H NMR data indicate the presence of six 
methyl groups [H 2.01 (3H, s), 1.77 (3H, d, J = 1.3 Hz), 1.19 (3H, s), 1.16 (3H, d, J = 
7.1 Hz), 1.13 (3H, s), and 1.00 (3H, d, J = 6.4 Hz)] and two double bonds [H 5.86 (1H, 
dd, J = 10.4, 2.1 Hz) and 5.78 (1H, dd, J = 9.7, 1.3 Hz)]. The 13C NMR spectrum of 1 
resolved 22 carbon resonances comprising two double bonds (C 142.0, 134.3, 139.9, 
and 131.3), an ester carbonyl group (C 170.3 and 21.2), two ketocarbonyl groups (C 
213.6 and 204.0), a quaternary carbon, five methyls, six methines (one oxygenated), 
and two methylenes. As five of the eight indices of hydrogen deficiency were accounted 
for by an ester carbonyl, two double bonds, and two ketocarbonyls, the remaining three 
indices of hydrogen deficiency required that 1 was tricyclic. The aforementioned 
spectroscopic data are similar to those of jatrointelones AG isolated from the other 
species in the same genus,16 implying that 1 likely possessed the same carbon 
frameworks. Three subunits, a (C-1 to C-3; C-16), b (C-5 to C-6; C-17), and c (C-8 to 
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C-9; C-11 to C-12) [Figure S1, Supporting Information], were established via the 1H-
1H COSY data. The linkage of subunits ac and other functionalities were deduced by 
the HMBC correlations (Figure S1, Supporting Information). The HMBC cross-peaks 
from H-5 to C-4, C-6, and C-15 and H-12 to C-13, C-14, and C-20, established the 4(5) 
and 12(13) double bonds, while the correlations from H3-18 to C-11, C-10, and C-9 
established the cyclopropane ring. The HMBC correlation from H-3 (H 5.41, d, J = 4.9 
Hz) to the acetoxy carbonyl at C 170.3 revealed that the acetoxy group was located at 
C-3. The HMBC correlations from H3-17 (H 1.16, d, J = 7.1 Hz) and H-9 (H 1.62) to 
C-7 suggested that a C-7 carbonyl group (C 213.6). The relative configuration of 1 was 
elucidated by the NOESY experiment (Figure S1, Supporting Information). The key 
NOESY interactions of H-15/H-6 and H-11/CH3-20, assigned the 4(5) and 12(13) 
double bonds as E configured. In the NOESY spectra, the correlations of H-9/H-11 
suggested a cis-orientation for the -oriented dimethylcyclopropane moiety. Thus, the 
NOESY cross-peaks of H-8/CH3-19, CH3-19/H-12, H-12/H-15, H-15/H-6, H-1/H-3, 
and H-3/H-5 assigned H-15, H-3, and H-6 as , while H3-16 was assigned an -
orientation according to the correlations of H3-16/H-1 (Figure S1, Supporting 
Information). The structure of 1 was confirmed through Cu K X-ray diffraction data 
analysis [Flack parameter, 0.2 (2)] (Figure 1). The absolute configuration of 1 was 
confirmed by experimental and calculated ECD data as 2R,3R,6R,9S,11R,15S-1 (Figure 
S2, Supporting Information). Thus, the structure of jatrogossone A (1) was established 
as (+)-(4E,12E,2R,3R,6R,9S,11R,15S)-3-acetoxylathyr-4,12-dien-7,14-dione. 
Compound 2 exhibited a molecular formula of C22H30O5, an oxygen atom mass unit 
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more than that of jatrogossone A (1). The NMR spectra of 2 showed a close structural 
resemblance to those of 1, except for the presence of a hydroxy group in 2, indicating 
that it was the oxygenated derivative of 1. The C-15 location of the hydroxy group was 
deduced by comparison of the 13C NMR chemical shift value of C-15 (C 51.7 in 1) and 
(C 83.3 in 2). The relative configuration of 2 was determined via the NOESY and NMR 
data, which showed the same features as those of 1. Compound 1 was assigned the same 
absolute configuration as 2 based on their similar ECD spectra, which included Cotton 
effects at 309 nm ( 2.95), 265 nm ( 3.54), and 220 nm ( 8.84), due to the n 
  (above 300 nm) and    (230−300 nm) transitions of the ,-unsaturated 
carbonyl moiety (Figure S3, Supporting Information). Thus, the structure of 
jatrogossone B (2) was identified as ()-(4E,12E,2R,3R,6R,9S,11R,15R)-3-
acetoxylathyr-4,12-dien-15-ol-7,14-dione. 
Compound 3 was assigned a molecular formula, C22H32O4 by its HRESIMS and 13C 
NMR data. The 1D NMR data of 3 showed close similarities those of 1, with the major 
differences being that a trisubstituted double bond in 3 was replaced by an sp3 methine 
C-13 (C 43.9) and an sp3 methylene C-12 (C 28.4) in 1, indicating that 3 is a 12,13-
dihydrogenated derivative of 1. This inference was confirmed by key HMBC 
correlations from H3-20 (H 1.11) to C-13 and C-12, as well as the 1H1H COSY 
correlations between H-12, H-13, and H-20. The NOESY correlations of H-13/H-15, 
H-15/H-2, H-15/H-3, H-15/H-6, H-6/H-13, H-6/H-8, and H-8/CH3-19 assigned H-
15, H-13, H-2, H-3, and H-6 as -oriented, while CH3-20 was assigned an -orientation. 
Thus, the relative configuration of 3 was determined to be 
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2R*,3R*,6R*,9S*,11R*,13R*,15S*. The absolute configuration of 3 was elucidated by 
comparing its calculated and experimental ECD spectra. The calculated ECD spectrum 
for enantiomer 2R,3R,6R,9S,11R,13R,15S showed a good fit with the experimental 
curve of 3 (Figure 2). Accordingly, the structure of jatrogossone C (3) was defined as 
()-(4E,2R,3R,6R,9S,11R,13R,15S)-3-acetoxylathyr-4-en-7,14-dione. 
Compound 4 had a molecular formula of C22H30O5, which was deduced from the 
HRESIMS spectrum (m/z 419.2073, [M  HCOO]−). The 1H NMR data of 4 revealed 
resonances characteristic for three olefinic protons [H 6.06 (1H, d, J = 1.8 Hz), 5.60 
(1H, dd, J = 15.4, 9.7 Hz), and 5.23 (1H, dd, J = 15.4, 9.2 Hz)], an oxygenated sp3 
methine proton [H 5.27 (1H, d, J = 4.6 Hz)], two terminal alkene methylene protons 
(H2-19) at H 4.81 and 4.79, and five methyl groups [H 2.10 (3H, s), 1.75 (3H, s), 1.37 
(3H, s), 1.24 (3H, d, J = 6.9 Hz), and 1.02 (3H, d, J = 6.8 Hz)]. Analysis of the 13C 
NMR data using DEPT revealed 22 carbon resonances comprising two ketocarbonyl 
groups (C 212.4 and 208.6), three double bonds (C 146.2, 140.2, 134.8, 134.4, 131.5, 
and 110.4), an ester carbonyl group (C 170.9 and 21.3), an oxygenated tertiary carbon 
(C 80.3), two methylenes, four methyls, and five sp3 methines (one oxygenated). The 
aforementioned information resembles those of the co-occurring known diterpenoid, 
integerrimene (10) 17, except for the presence of an oxygenated tertiary carbon in 4, 
indicating that it was the oxygenated derivative of 10. The hydroxylation at C-6 was 
verified by the HMBC correlations from both H3-17 (H 1.37) and H-5 (H 6.06) to C-
6. The key NOESY interaction of H-15/OH-6 and a coupling constant of 15.4 Hz 
between H-11 and H-12, assigned the 4(5) and 11(12) double bonds as E configured. 
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The NOESY correlations of H-8/H-11, H-11/H-13, H-13/H-15, H-15/OH-6, H-15/H-
3 assigned H-3, HO-6, H-13, and H-15 as -oriented, while correlations of H3-16/H-1 
and H-9/H-8 assigned H3-16 and H-9 as -orientated (Figure S4, Supporting 
Information). Compound 4 was assigned the same absolute configuration as 10 based 
on their similar ECD spectra, which included Cotton effects at 200 nm ( 8.66) and 
310 nm ( 2.23) (Figure S5, Supporting Information). The structure of compound 10 
including absolute configuration was confirmed through Cu K X-ray diffraction data 
analysis [Flack parameter, 0.15 (11)] (Figure 3). Therefore, the structure of 
jatrogossone D (4) was established as ()-(4E,12E,2R,3R,6S,9S,13R,15S)-3-acetoxy-
10,11-secolathyr-4,11-dien-6-ol-7,14-dione. 
Compound 5 was assigned a molecular formula of C20H28O3 from the HRESIMS 
data (m/z 334.2376 [M + NH4]+). The NMR data of 5 resembled those of 10, except for 
the absence of signals for an acetyl group and supported by an upfield-shifted resonance 
of H-3 at H 4.00 (1H, dd, J = 10.2, 4.0 Hz), indicating that 5 was the 3-deacetylated 
derivative of 10. The relative configuration of 5 was determined via the NOESY and 
NMR data, which showed the same features as those of 10. Compound 5 was assigned 
the same absolute configuration as 10 based on their similar ECD spectra (Figure S5, 
Supporting Information). Thus, the structure of jatrogossone E (5) was determined as 
()-(4E,12E,2R,3R,6R,9S,13R,15S)-10,11-secolathyr-4,11-dien-3-ol-7,14-dione.  
Compound 6 had a molecular formula of C22H30O4, as established by the HRESIMS 
ion at m/z 381.2029 [M + Na]+ (calcd for C22H30O4Na, 381.2036). The NMR spectra of 
6 closely resembled those of 10, except for replacement of the 4(5) double bond in 10 
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by the 5(6) double bond in 6. The location of the 5(6) double bond was supported by 
HMBC cross-peaks from H3-17 (H 1.93) to C-5, C-6, and C-7. The NOESY 
correlations of H-15/H-4 and H-4/H-2 assigned a -orientation for H-4. Compound 6 
was assigned the same absolute configuration as 10 based on their similar ECD spectra, 
which included Cotton effects at 200 nm ( +5.62) and 297 nm ( 2.20) (Figure S5, 
Supporting Information). Hence, the structure of jatrogossone F (6) was defined as ()-
(5Z,11E,2R,3R,4S, 9S,13R,15S)-3-acetoxy-10,11-secolathyr-5,11-dien-7,14-dione. 
Compound 7, an amorphous solid, had a molecular formula of C22H32O4 as 
established by the HRESIMS ion at m/z 378.2644 [M + NH4]+, corresponding to seven 
indices of hydrogen deficiency. Its 1H NMR data indicate the presence of an olefinic 
proton [H 5.80 (1H, dd, J = 3.3, 3.2 Hz)], an oxygenated sp3 methine proton [H 5.40 
(1H, d, J = 3.6 Hz)], and six methyl groups [H 0.94 (3H, s), 0.97 (3H, d, J = 6.2 Hz), 
1.06 (3H, s), 1.13 (3H, d, J = 7.3 Hz), 1.23 (3H, d, J = 6.9 Hz), and 2.01 (3H, s)]. The 
13C NMR spectrum of 7 revealed 22 carbon resonances including a ketocarbonyl group 
(C 207.3), a trisubstituted double bond (C 144.9 and 132.1), an ester carbonyl group 
(C 170.6 and 21.4), five methyls, eight sp3 methines (one oxygenated), two methylenes, 
a quaternary carbon, and an oxygenated tertiary carbon. The abovementioned analysis 
accounted for three out of seven indices of hydrogen deficiency, suggesting that 7 had 
a tetracyclic carbon backbone. These data were similar to those of 3, except for the 
difference of ring topology, indicating the linkage between C-8 and C-14 in 7. This 
tetracyclic ring topology was also supported by the putative biosynthetic pathway.18 
Finally, this deduction was verified by HMBC cross-peaks from H3-20 (H 1.13) to C-
 10 
 
14 and H-8 (H 2.22) to C-7, C-9, C-13, C-14, and C-15. The detailed interpretation 
(Figure S6, Supporting Information) of its 2D NMR data allowed the establishment of 
the 2D structure of 7. The relative configuration of 7 was assigned as similar to 3 by 
analyzing the NOESY data (Figure S6, Supporting Information). The NOESY cross-
peaks of CH3-19/H-12, CH3-19/H-8, and H-8/H-15 assigned H-8 as -oriented, while 
HO-14 was assigned an -orientation according to the correlations of HO-14/H-1, and 
HO-14/H3C-20. Thus, the relative configuration of 7 was assigned as 
2R*,3R*,6R*,8S*,9R*,11R*,13R*,14S*,15S*. The absolute configuration of 7 was 
confirmed by comparing its calculated and experimental ECD spectra. The calculated 
ECD spectrum for enantiomer 2R,3R,6R,8S,9R,11R,13R,14S,15S showed a good fit 
with the experimental curve of 7 (Figure 4). Therefore, the structure of jatrogossone G 
(7) was defined as (+)-(4E,2R,3R,6R,8S,9R,11R,13R,14S,15S)-3-acetoxytiglia-4-en-
14-ol-7-one.  
Compound 8 was obtained as colorless crystals. The HRESIMS data exhibited a 
sodium adduct ion [M + Na]+ at m/z 337.1799 (calcd for 337.1774 corresponding to a 
molecular formula of C20H26O3. The 1H NMR data exhibited resonances characteristic 
of an olefinic proton [H 5.82 (1H, s)] and five methyl groups [H 1.91 (3H, d, J = 1.6 
Hz), 1.36 (3H, s), 1.28 (3H, s), 1.07 (3H, d, J = 6.9 Hz), and 0.88 (3H, s)]. The 13C 
NMR spectrum exhibited the presence of 20 carbon resonances, including three 
ketocarbonyl groups (C 215.3, 213.3, and 208.0), two double bonds (C 141.9, 138.3, 
141.6, and 127.6), five methyls, four methylenes, two methines, and two quaternary 
carbons. As five of the eight indices of hydrogen deficiency were accounted for by two 
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double bonds and three ketocarbonyl groups, the remaining three indices of hydrogen 
deficiency required that 8 was tricyclic. These spectroscopic data are similar to those 
of jatrophatrione,19 which was isolated from other species in the same genus. 
Comparison with jatrophatrione, showed that a 3(4) double bond in jatrophatrione was 
replaced by a 4(15) double bond in 8. This assignment was verified by HMBC 
correlations from H-3a (H 2.59) to C-15 (C 138.3). The relative configuration of 8 
was the same as that of jatrophatrione by analysis of the NOESY correlations (Figure 
S7, Supporting Information). The absolute configuration of 8 was confirmed through 
Cu K X-ray diffraction data analysis [Flack parameter, 0.12 (13] (Figure 5). 
Consequently, the structure of compound 8 was elucidated and named jatrogossone H. 
Compound 9 had the same molecular formula (C20H26O3) as 8 based on their 
HRESIMS data. The NMR data of 9 closely resembled those of 8, with differences 
being due to the orientation of CH3-16 (H 1.03 and C 20.9 in 9; H 1.07 and C 21.7 in 
8), indicating that compound 9 was a C-2 epimer of 8. Therefore, the -oriented CH3-
16 group was assigned in 9. Compound 9 was assigned the same absolute configuration 
as 8 based on their similar ECD spectra, which included Cotton effects at 250 nm ( 
1.07) and 323 nm ( +0.51) (Figure S8, Supporting Information). Therefore, the 
structure of jatrogossone I (9) was assigned as shown. 
Additionally, six known compounds were identified as integerrimene (10),17 
jatrophone (11),10 jatrogrossidione (12),20 citlalitrione (13),21 jatropholone B (14),8 and 
jatropholone A (15).8  
Cytotoxic Effect of Isolates Against RKO and LOVO Cells. The growth inhibitory 
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properties of the 5-fluorouracil (5-FU) and 15 diterpenoids (1−15) were investigated by 
the CCK-8 metabolism assay, and the IC50 values were calculated after 48 h of treatment. 
We considered any diterpenoid compound exhibiting an inhibition rate of less than 50% 
at 20 M to be inactive. The results showed that compounds 110 and 1315 did not 
inhibit RKO and LOVO growth, while compounds 11 and 12 showed moderate 
inhibitory activities with IC50 values on LOVO at 18.6 and 14.5 M, respectively. 
Compounds 11 and 12 were the most active compounds with IC50 values on RKO at 
8.0 and 2.6 M, respectively; the positive 5-Fu positive control had IC50 values on RKO 
and LOVO of 10.2 and 11.5 M (Figure 6), respectively. 
Morphological Changes of RKO Cells Treated with Jatrogrossidione (12). To 
investigate the mechanism underlying the antitumor activity of compound 12, RKO 
cells were further examined in fluorescence photomicrographs of RKO cells stained 
with DAPI after treatment for 24 h with 2.6 and 5.2 M of 12. Afterwards, the 
morphological characteristic features of apoptosis were examined under fluorescence 
or inverted light microscopy. The fragmentation of the nucleus, condensation of 
chromatin, and morphological characteristic features of apoptosis were examined. 
Control cells showed homogeneous and round nuclei, whereas cells treated with 12 
showed condensed and fragmented nuclei (arrows) (Figure 7). As shown in Figure 7, a 
2-fold increase in IC50 to 5.2 M induces a significant increase of apoptosis in RKO 
cells. 
Antimigratory Activity of Jatrogrossidione (12) in RKO Cells. The wound-
healing properties were used as a tool to study the directional cell migration in vitro.22 
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The effects of 12 in inhibiting the migration of RKO cells were examined by wound-
healing assays. To investigate the effect of 12 on migration, RKO cells were treated 
with 2.6 and 5.2 M of 12 for 48 h. After incubation, the wound was measured by 
comparing it to the original wound width. This analysis method was used to assess the 
antimigration activity of diterpenoids. Compared with the positive control 5-FU, the 
comparable antimigration activity of 12 is shown on RKO cells in Figure 8. 
Jatrogrossidione (12) Induces Cell Cycle Arrest at the G2/M Phase in RKO Cells. 
To elucidate the mechanism of the anti-proliferative activity of 12, its effect on cell 
cycle distribution was analyzed by flow cytometry. As shown in Figure 9, compound 
12 arrested the growth of cells at the G2/M phase, increasing from 10.97% of cells 
treated with the negative control to 18.30% and 25.76% of cells treated with 2.6 and 
5.2 M of 12, respectively. These results show that 12 inhibits proliferation of RKO 
cells via the induction of G2/M phase arrest. 
Jatrogrossidione (12) Causes RKO Cell Death by Apoptosis. To clarify the 
mechanism of 12-induced RKO cell death, annexin V-FITC and propidium iodide (PI) 
co-staining and flow cytometric analysis were performed. As shown in Figure 10, 
compound 12 could induce efficient apoptosis of RKO. When compared with the 
control (5.89%, early and late apoptosis), treatment with 12 increased the apoptosis 
rates, which gradually increased from 39.7 to 89.7% after treatment with 2.6 and 5.2 
M of 12, respectively. The results show that 12 caused a remarkable increase in 
cellular apoptosis in a dose-dependent manner. 
 
EXPERIMENTAL SECTION 
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General Experimental Procedures. The detailed instruments and 
spectroscopic measurements for the purified compounds and the materials for the 
isolation of the diterpenoids from J. gossypiifolia are presented in the Supporting 
Information. 
Plant Material. Branches and leaves of J. gossypiifolia were collected in November 
2015, Shennong Herbal Garden, Guangzhou city, People’s Republic of China, and was 
identified by Professor L.-P. Qin. A sample (SJGZ-201511) was deposited at our Central 
Laboratory. 
Extraction and Isolation. The branches and leaves of J. gossypiifolia (5 kg) were 
pulverized and soaked with 95 ethanol (3  25L) at room temperature, and the 
solvent was evaporated in vacuo to give a crude extract (121 g). The concentrated 
extract was suspended in H2O and fractionated with petroleum ether and EtOAc, 
respectively. The petroleum ether extract (31 g) was chromatographed over MCI 
gel with MeOH/H2O (30% to 100%, v/v) to afford four fractions (I−IV). Fr. II 
(6.0 g) was separated on a Sephadex LH-20 column with MeOH to give four 
fractions (IIaIId). Fr. IIb (1.8 g) was passed through a silica gel (petroleum 
ether/EtOAc, 1:0  0:1, v/v) to give Fr. IIb1–Fr. IIb3. Fr. IIb2 was separated over 
a column of Sephadex LH-20 with MeOH/CH2Cl2 (1:1, v/v) to give 2 (10.2 mg). Fr. 
IIb3 was purified by a semi-preparative method with a YMC column (MeOH/H2O, 
7:3), to give 14 (6.1 mg) and 15 (7.2 mg). Fr. IIc (2.9 g) was chromatographed on a 
silica gel column using gradient elution with petroleum ether/EtOAc to yield three 
fractions (IIc1–IIc3). Fr. IIc2 was puriﬁed by reversed-phase HPLC (MeOH/H2O, 
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7:3) to yield 7 (6.1 mg) and 12 (8.8 mg). Fr. IIc3 was separated by RP-HPLC 
(MeOH/H2O, 7:3), to give 8 (4.2 mg), 9 (2.5 mg), and 13 (2.5 mg). Fr.III (6.5 g) was 
separated over a column of Sephadex LH-20 with MeOH to afford five fractions 
(IIIaIIIe). Fr. IIIa (3.2 g) was separated over an RP-C18 column with gradient 
elution with MeOHHO to give four fractions (IIIa1IIIa4). Fr. IIIa2 was 
separated over a column of Sephadex LH-20 with MeOH/CH2Cl2 (1:1) to yield 6 (7.2 
mg). Fr. IIIa3 was separated over RP-HPLC (H2O/MeOH, 2:8), to give 2 (6.8 mg), 
1 (6.2 mg), and 3 (5.8 mg). Fr. IIIb (2.0 g) was separated over a column of Sephadex 
LH-20 to yield Fr. IIIb1–Fr. IIIb3. Fr. IIIb1 was separated by RP-HPLC (H2O/MeOH, 
4:6), to yield 5 (4.5 mg), 4 (5.4 mg), and 10 (11.2 mg).  
Jatrogossone A (1): colorless crystals; mp 165−167C; []25D +45 (c 0.2, MeOH); 
UV (MeOH) max (log ) 207 (3.96), 262 (3.84) nm; ECD (c 1.2  104 M, MeOH) max 
() 223 (7.28), 290 (2.28) nm; IR (KBr) max 2931, 1735, 1717, 1686, 1454, 1371, 
1237, 1058, 868 cm1; 1H and 13C NMR, see Tables 1 and 2; HRESIMS m/z 376.2479 
[M + NH4]+ (calcd for C22H34O4N, 376.2482).  
Jatrogossone B (2): an amorphous solid; []25D 24 (c 0.2, MeOH); UV (MeOH) 
max (log ) 208 (4.33), 267 (4.13) nm; ECD (c 1.3  104 M, MeOH) max () 220 
(8.84), 309 (2.95) nm; IR (KBr) max 3459, 2926, 2930, 1737, 1709, 1664, 1595, 
1370, 1235, 1048, 898 cm1; 1H and 13C NMR, see Tables 1 and 2; HRESIMS m/z 
397.1971 [M + Na]+ (calcd for C22H30O5Na, 397.1985). 
Jatrogossone C (3): an amorphous solid; []25D +42 (c 0.1, MeOH); UV (MeOH) 
max (log ) 210 (3.78), 264 (2.84), 300 (3.95) nm; ECD (c 1.4  104 M, MeOH) max 
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() 229 (2.84), 296 (4.10) nm; IR (KBr) max 2961, 2931, 1732, 1706, 1455, 1371, 
1237, 1049, 886 cm1; 1H and 13C NMR, see Tables 1 and 2; HRESIMS m/z 378.2638 
[M + NH4]+ (calcd for C22H36O4N, 378.2638).  
Jatrogossone D (4): an amorphous solid; []25D 16 (c 0.2, MeOH); UV (MeOH) 
max (log ) 208 (3.61) nm; ECD (c 1.3  104 M, MeOH) max () 200 (8.67), 310 
(2.23) nm; IR (KBr) max 2928, 1714, 1456, 1377, 1239, 1020 cm1; 1H and 13C NMR, 
see Tables 1 and 2; HRESIMS m/z 419.2073 [M + COOH] (calcd for C23H31O7, 
419.2075). 
Jatrogossone E (5): an amorphous solid; []25D 11 (c 0.2, MeOH); UV (MeOH) 
max (log ) 208 (3.41) nm; ECD (c 1.5  104 M, MeOH) max () 200 (5.03), 300 
(1.84) nm; IR (KBr) max 2925, 1734, 1710, 1456, 1376, 1236, 1019, 976, 891 cm1; 
1H NMR see Table 1 and 13C NMR see Table 2; HRESIMS m/z 334.2376  [M + NH4]+ 
(calcd for C20H32O3N, 334.2377). 
Jatrogossone F (6): an amorphous solid; []25D 184 (c 0.1, MeOH); UV (MeOH) 
max (log ) 209 (3.87) nm; ECD (c 1.1  104 M, MeOH) max () 200 (+5.62), 297 
(2.20) nm; IR (KBr) max 2929, 1735, 1710, 1456, 1375, 1238, 1018, 975 cm1; 1H 
NMR see Table 1 and 13C NMR see Table 2; HRESIMS m/z 381.2029 [M + Na]+ (calcd 
for C22H30O4Na, 381.2036). 
Jatrogossone G (7): an amorphous solid; []25D +18 (c 0.1, MeOH); UV (MeOH) 
max (log ) 210 (3.65), 290 (3.01) nm; ECD (c 1.3  104 M, MeOH) max () 213 
(+18.18), 297 (10.10) nm; IR (KBr) max 2925, 2872, 1735, 1710, 1456, 1377, 1237, 
1017, 974, 880 cm1; 1H NMR see Table 1 and 13C NMR see Table 2; HRESIMS m/z 
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378.2644 [M + NH4]+ (calcd for C22H36O4N, 378.2639). 
Jatrogossone H (8): colorless crystals; mp 183−185C; []25D +62 (c 0.1, MeOH); 
UV (MeOH) max (log ) 210 (3.36) nm; ECD (c 1.2  104 M, MeOH) max () 250 
(+1.16), 323 (+0.48) nm; IR (KBr) max 2956, 1751, 1697, 1378, 1062 cm1; 1H NMR 
see Table 1 and 13C NMR see Table 2; HRESIMS m/z 337.1799 [M + Na]+ (calcd for 
C20H26O3Na, 337.1774). 
Jatrogossone I (9): white powder; []25D 40 (c 0.1, MeOH); UV (MeOH) max (log 
) 208 (3.45) nm; ECD (c 1.2  104 M, MeOH) max () 250 (+1.07), 323 (+0.51) nm; 
IR (KBr) max 2957, 2926, 1748, 1698, 1456, 1377, 1237, 1086, 1017, 891, 725 cm1; 
1H NMR see Table 1 and 13C NMR see Table 2; HRESIMS m/z 337.1764 [M + Na]+ 
(calcd for C20H26O3Na, 337.1774). 
Integerrimene (10): colorless crystals; mp 171−173C; []25D 21 (c 0.2, MeOH); 
UV (MeOH) max (log ) 208 (3.58) nm; ECD (c 1.2  104 M, MeOH) max () 200 
(4.66), 315 (2.50) nm; IR (KBr) max 2962 2931, 1733, 1714, 1455, 1370, 1238, 1016, 
986, 896 cm1; HRESIMS m/z 376.2487 [M + NH4] (calcd for C22H34O4N, 376.2482). 
Cell Culture. RKO and LOVO human colon cancer cell lines were obtained from 
Cell Bank of Chinese Academy of Sciences (Shanghai, China). Cells were cultivated 
in MEM or RPMI supplemented with 10% fetal bovine serum and 1% penicillin and 
streptomycin at 37 C in a humidified incubator containing 5% CO2. 
Cell Viability Assay. Cell proliferation was analyzed using WST-8 Cell Counting 
Kit-8. RKO cells were suspended in fresh MEM at a density of 68 × 104 cells/mL in a 
96-well plate. Cells were treated with jatrogrossidione at various concentrations (0.625, 
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1.25, 2.5, 5, 10, 20, and 40 M) for 48 h, and CCK-8 solution (10 L) was added to the 
cultures and incubated for 1 h at 37 C. A microplate reader (American Bio-Tek) at 450 
nm was used to measure the optical density. The percentage of survivors in untreated 
control wells represented the survival of the cells. Assays were conducted as three 
independent experiments. 
DAPI Staining. After a 24 h treatment with jatrogrossidione at the IC50 and 2-fold 
IC50 concentrations, DMSO, and 5-FU, cells were settled in 4% paraformaldehyde for 
10 min and washed three times with phosphate-buffered saline (PBS). The cells were 
incubated with DAPI (Beyotime, Jiangsu, China) for 15 min, and washed again three 
times with PBS. Finally, the DAPI-stained cells were photographed using a 
fluorescence microscope (Olympus IX-73, Tokyo, Japan). 
Cell Migration Assay. The RKO cells were seeded in six-well dishes and reached 
over 90% conﬂuence in the wells. The cell monolayer was wounded by a sterile 100 L 
tip, and the debris was washed with PBS. Afterwards, the RKO cells were transferred 
to 2% fetal bovine serum MEM medium at 37 °C. The cells were added sequentially: 
DMSO, 5-FU, or jatrogrossidione at 1/2-fold IC50 and IC50 concentrations. The 
migration of cells into wounded areas was measured and photographed at 0 h and 48 h 
with an inverted microscope. The areas of the scratches were analyzed by Image-Pro 
Plus 6.0 software.  
Cell Cycle Analysis. The RKO cells were processed with DMSO, 5-FU or 
jatrogrossidione at IC50 and 2-fold IC50 concentrations at 37 °C for 24 h in a 6-well 
plate, harvested, and washed twice with PBS. A volume containing 1×106 cells were 
 19 
 
settled with 1 mL ice-cold 70% (v/v) EtOH, and deposited at 4 °C, and finally stained 
with PI solution containing RNase at 37 °C for 30 min. The cell cycle was assayed by 
a FACSCalibur flow cytometer (BD Biosciences) and the proportion of cells at various 
periods was calculated by the Modfit LT 5.0 software. 
Flow Cytometric Analysis of Cell Apoptosis. The intensity of apoptosis of cells 
was evaluated through the annexin V-fluorescein isothiocyanate (FITC) apoptosis 
detection kit, according to the manufacturer’s instructions. The RKO cells were 
incubated with DMSO, 5-FU, or jatrogrossidione at IC50 and 2-fold IC50 concentrations 
at 37 °C in a six-well plate for 24 h, collected and washed twice with PBS, gently 
resuspended in binding buffer, incubated with annexin V-FITC (5 L) and PI (5 L) in 
the dark for 20 min at 37 °C, and analyzed immediately by flow cytometry. 
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Table 1. 1H NMR Data of Jatrogossones A−G (1−9) in CDCl3 (600 MHz,  in ppm, J in Hz)  
position 1 2 3 4 5 6 7 8 9 
1a 2.17, m 2.04, m 2.20, dd 
(15.0, 8.3) 
2.15, dt 
(12.5, 8.7) 
2.19, dd 
(13.0, 9.0) 
1.89, m 2.04, m 2.70, m 2.71, m 
1b 2.04, m 1.72, m 1.99, m 1.80, ddd 
(12.5, 10.8, 
7.5) 
1.48, m 1.83, m 1.91, m 2.19, m 2.15, m 
2 2.06, m 2.61, m 2.02, m 2.03, m 1.88, m 2.13, m 1.90, m 2.41, m 2.46, m 
3 5.41, d (4.9) 5.80, d (5.2) 5.10, d (3.9) 5.27, d (4.6) 4.00, dd 
(10.2, 4.0) 
5.26, dd (5.6, 
5.4); 3.72, m 
5.40, d (3.6) 2.59, m; 
2.06, m 
2.56, m; 
2.06, m 
4      3.72, m    
5 5.86, dd 
(10.4, 2.1) 
6.07, d (11.0) 5.77, dd 
(10.3, 1.9) 
6.06, d (1.8) 5.57, d (10.0) 5.36, dd 
(10.7, 1.4) 
5.80, dd (3.3, 
3.2) 
5.82, s 5.81, d (1.6) 
6 3.31, dd 
(10.4,7.1) 
2.98, dd 
(11.0,7.0) 
3.68, dd 
(10.3, 6.6) 
 3.30, m  3.43, m   
8a 2.52, dd 
(14.8, 7.1) 
2.40, dd 
(14.6, 5.7) 
2.46, dd 
(13.4, 1.4) 
3.41, dd 
(11.9, 11.8) 
2.76, dd 
(11.5, 11.4) 
2.92, dd 
(15.3, 5.9) 
2.22, d (9.6) 2.80, dd 
(14.2, 2.9) 
2.77, dd 
(14.2, 2.9) 
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8b 2.28, dd 
(14.8, 10.9) 
2.09, m 2.10, dd 
(13.4, 10.8) 
2.36, dd 
(11.9, 3.9) 
2.40, dd 
(11.0, 3.9) 
2.49, dd 
(15.3, 12.2) 
 2.51, d (14.2) 2.50, d (14.2) 
9 1.62, m 1.70, m 0.59, m 2.98, m 2.91, m 3.10, m 1.34, dd (9.6, 
9.3) 
2.61, d (2.9) 2.62, d ( 2.9) 
11a 1.39, dd (9.7, 
9.6) 
1.42, dd (9.7, 
9.6) 
0.36, m' 5.60, dd 
(15.4, 9.7) 
5.67, dd 
(15.2, 10.1) 
5.44, dd 
(15.0, 10.1) 
0.83, m 2.55, d (16.3) 2.56, d (16.3) 
11b        2.31, d (16.3) 2.30, d (16.3) 
12a 5.78, dd (9.7, 
1.3) 
6.26, d (9.8) 1.94, m 5.23,dd 
(15.4, 9.2) 
5.00, dd 
(15.2, 9.9) 
4.92, dd 
(15.0, 10.1) 
1.54, m   
12b   1.22, m    1.06, m   
13   3.21, m 3.24, dd (9.2, 
6.9) 
3.45, dd  
(9.9, 6.5) 
 2.17, dd  
(13.9, 6.7) 
  
15 3.71, dd (8.0, 
2.2) 
 3.78, m 4.12, dd (8.5, 
8.2) 
1.77, m 3.22, m 2.96, m   
16 1.00, d (6.4) 1.01, d (6.9) 1.04, d (6.2) 1.02, d (6.8) 1.09, d (6.7) 0.95, d (6.9) 0.97, d (6.2) 1.07, d (6.9) 1.03, d (6.8) 
17 1.16, d (7.1) 1.11, d (7.0) 1.16, d (6.7) 1.37, s 1.21, d (7.2) 1.93, d (1.43) 1.23, d (6.9) 1.91, d (1.6) 1.91, d (1.6) 
18 1.13, s 1.25, s 0.82, s 1.75, s 1.75, s 1.73, s 0.94, s 0.88 , s 0.88 , s 
19a 1.19, s 1.15, s 0.96, s 4.81, s 4.84, s 4.79, s 1.06, s 1.28, s 1.27, s 
19b    4.79, s 4.77, s 4.76, s    
20 1.77, d (1.3) 1.88, s 1.11, d (6.7) 1.24, d (6.9) 1.13, d (6.5) 1.09, d (6.5) 1.13, d (7.3) 1.36, s 1.34, s 
3-OAc 2.01, s 2.10, s 1.96, s 2.10, s  2.11, s 2.01, s   
 
 
 
 
Table 2. 13C NMR Data of Jatrogossones A−G (1−9) in CDCl3 (150 MHz,  in ppm) 
position 1 2 3 4 5 6 7 8 9 
1 33.6, CH2 47.3, CH2 33.0, CH2 36.8, CH2 37.2, CH2 35.5, CH2 33.8, CH2 44.9, CH2 44.8, CH2 
2 37.2, CH 36.1, CH 37.4, CH 36.8, CH 39.8, CH 37.5, CH 37.2, CH 32.8, CH 32.5, CH 
3 80.5, CH 79.3, CH 81.8, CH 82.7, CH 79.9, CH 78.5, CH 80.4, CH 45.1, CH2 45.2, CH2 
4 139.9, C 138.6, C 139.4, C 140.2, C 143.1, C 44.6, CH 144.9, C 141.9, C 141.8, C 
5 131.3, CH 135.8, CH 132.1, CH 134.8, CH 127.0, CH 132.2, CH 132.1, CH 127.6, C 127.8, C 
6 50.2, CH 50.2, CH 47.9, CH 80.3, C 49.0, CH 139.1, C 47.7, CH 141.6, C 141.4, C 
7 213.6, C 213.2, C 210.9, C 212.4, C 211.1, C 205.7, C 207.3, C 208.8, C 208.9, C 
8 36.7, CH2 36.8, CH2 39.5, CH2 41.3, CH2 45.0, CH2 47.1, CH2 59.2, CH 39.3, CH2 39.2, CH2 
9 30.5, CH 32.6, CH 23.5, CH 47.7, CH 48.8, CH 46.6, CH 20.0, CH 51.4, CH 51.3, CH 
10 23.2, C 24.2, C 18.4, C 146.2, C 145.6, C 145.9, C 17.6, C 37.4, C 37.4, C 
11 25.9, CH 26.0, CH 23.4, CH 134.4, CH 134.8, CH 132.7, CH 18.3, CH 55.8, CH2 55.8, CH2 
12 134.3, CH 143.7, CH 28.4, CH2 131.5, CH 131.0, CH 132.3, CH 26.5, CH2 215.3, C 215.4, C 
13 142.0, C 138.6, C 43.9, CH 53.1, CH 53.0, CH 52.5, CH 38.5, CH 64.6, C 64.3, C 
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14 204.0, C 205.7, C 210.5, C 208.6, C 216.0, C 210.2, C 78.6, C 213.3, C 213.0, C 
15 51.7, CH 83.3, C 52.6, CH 51.0, C 50.6, C 53.0, CH 54.6, CH 138.3, C 138.1, C 
16 13.9, CH3 13.0, CH3 13.6, CH3 13.7, CH3 13.6, CH3 14.8, CH3 13.4, CH3 21.7, CH3 20.9, CH3 
17 18.0, CH3 17.4, CH3 17.5, CH3 29.2, CH3 17.6, CH3 20.3, CH3 15.1, CH3 19.3,CH3 19.4,CH3 
18 15.6, CH3 15.5, CH3 15.3, CH3 21.4, CH3 21.3, CH3 21.1, CH3 14.8, CH3 27.8, CH3 27.9, CH3 
19 28.3, CH3 28.2, CH3 28.5, CH3 110.4, CH2 110.2, CH2 110.7, CH2 28.3, CH3 23.8, CH3 23.8, CH3 
20 14.2, CH3 13.7, CH3 18.2, CH3 16.6, CH3 16.0, CH3 15.7, CH3 18.3, CH3 14.9, CH3 14.8, CH3 
3-OAc 170.3, C 170.5, C 170.9 170.9  170.9 170.6   
 21.2, CH3 21.3, CH3 21.3, CH3 21.3, CH3  21.0, CH3 21.4, CH3   
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Figure 1. ORTEP diagram of compound 1. 
 
 
 
 
Figure 2. Experimental ECD spectrum (210400 nm) of 3 and the calculated ECD 
spectra of the model molecules of 3 at the B3LYP/6-311++G (d, p) level in the gas 
phase. 
 26 
 
 
 
Figure 3. ORTEP diagram of compound 10. 
 
 
Figure 4. Experimental ECD spectrum (210400 nm) of 7 and the calculated ECD 
spectra of the model molecules of 7 at the B3LYP/6-311++G(d, p) level in the gas 
phase. 
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Figure 5. ORTEP diagram of compound 8. 
 
Figure 6. Inhibitory curves of compounds 11, 12, and 5-FU (positive control) in RKO 
cells. 
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Figure 7. Evaluation of effects on apoptosis by compound 12. Evaluation of changes 
in nuclear morphology by ﬂuorescence microscopy of DAPI-stained nuclei after 24 h 
of incubation of RKO human colon cancer cells with compounds 12, 5-FU, or DMSO 
vehicle control. Representative images of compound effect on apoptosis (200 × 
magniﬁcation), with red arrows highlighting apoptotic cells. aIC50, b2-fold IC50. 
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Figure 8. Wound-healing assays by compound 12 with human colon cancer cell RKO. 
The incubation of 12, 5-FU, or DMSO with tumor cells (a). The antimigration effects 
of 12, 5-FU, or DMSO on the tumor cells (b). a1/2-fold IC50, bIC50, p < 0.05, p < 0.01. 
 
 
 
Figure 9. Effects of compound 12 on cell cycle distribution. RKO human colon cancer 
cells were treated with compounds 12, 5-FU, or DMSO vehicle control for 24 h then 
harvested, stained with PI, and analyzed by ﬂow cytometry. Following ﬂow cytometry 
analysis, frequencies of cells in each phase of the cell cycle were calculated using Mod 
Fit LT 5.1 software. aIC50, b2-fold IC50. 
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Figure 10. Apoptosis in RKO cells induced by 12. RKO cells were treated with 12, 5-
FU, or DMSO for 24 h and then harvested, stained with annexin V/PI, and analyzed by 
ﬂow cytometry. aIC50, b2-fold IC50. 
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